What is tesamorelin (Egrifta)?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) — the hypothalamic peptide that tells the pituitary gland to make and release growth hormone (GH). It is sold under the brand name Egrifta. Rather than supplying GH directly, tesamorelin acts one step upstream: it stimulates the pituitary to release the body’s own GH in a pulsatile pattern, which more closely mirrors normal physiology than a steady dose of injected GH.
Once GH rises, it signals the liver to produce IGF-1 (insulin-like growth factor 1), the downstream messenger behind many of GH’s tissue-level effects — including the mobilization of stored fat, particularly visceral (deep abdominal) fat. In the pivotal clinical trial, IGF-1 rose 81.0% on tesamorelin while it slipped about 5% on placebo, confirming the drug is engaging that GHRH → GH → IGF-1 axis as intended.
That mechanism is why tesamorelin draws so much interest. But mechanism is not the same as approval, and approval is not the same thing for every use. The rest of this page keeps those distinctions sharp, because with tesamorelin they matter more than usual.
What is it actually FDA-approved for?
Tesamorelin has exactly one FDA-approved indication: the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. That is the full scope of its approval — not weight loss in general, not body recomposition, not anti-aging, and not GH optimization in healthy people.
HIV-associated lipodystrophy is a specific, recognized complication seen in some people living with HIV and on certain antiretroviral therapies: excess visceral fat builds up in the abdomen, often alongside metabolic changes. Tesamorelin was developed, trialed, and approved specifically to address that fat accumulation in that population. The pivotal 2007 trial in the New England Journal of Medicine showed visceral adipose tissue fell 15.2% over 26 weeks on tesamorelin while rising 5.0% on placebo, and a later review confirmed that reduction was maintained in patients who kept treatment through week 52.
The approved labeling is also explicit about what tesamorelin is NOT for. It is not indicated for weight-loss management — the label describes a weight-neutral effect, meaning it shifts where fat sits rather than dropping the number on the scale. The label further notes that long-term cardiovascular benefit and safety have not been established, and it was never studied as a general anti-aging or muscle-building agent. In other words, even the approved use comes with stated limits, and those limits are part of the approval, not fine print to skim past.
What is the approved dose — and why the “2 mg” figure needs context
The dose that built tesamorelin’s evidence base is 2 mg injected subcutaneously once daily. That is the amount used in the randomized trials — the 2007 NEJM trial and a later 2014 JAMA trial both dosed participants at tesamorelin 2 mg daily — and it is the regimen that was reviewed for the original approval. The original Egrifta was supplied as a powder reconstituted before injection, given into the abdomen with rotated sites to limit skin reactions.
Here is a detail many “tesamorelin dosing” pages get wrong, so it is worth stating plainly: the current FDA-approved products are reformulations whose label numbers are lower than 2 mg, because they are absorbed more efficiently and are designed to deliver comparable drug exposure. The newer EGRIFTA WR label, for example, specifies 1.28 mg subcutaneously once daily, and an earlier reformulation (EGRIFTA SV) is labeled 1.4 mg. So the “right” milligram number is not a single fixed value you can copy from a forum — it is tied to the specific product and formulation a prescriber is using.
Either way, the critical caveat is the same: every one of those figures is a treatment dose for one disease, prescribed and supervised by a doctor. None is a generic "tesamorelin dose," and none is evidence that the same regimen is appropriate, safe, or effective for anyone outside that indication. The approved dose carries the weight of regulatory review only when it is used for the thing it was approved for. Reading any of these numbers as a green light for personal anti-aging or physique use is exactly the leap this page is warning against.
What does the trial evidence actually show?
It is worth being concrete about what the studies found, because the approved claim rests on real, measured results rather than mechanism alone. In the pivotal NEJM trial, the headline outcome was a 15.2% drop in visceral adipose tissue over 26 weeks on tesamorelin versus a 5.0% increase on placebo — a genuine, statistically meaningful separation, in the HIV-lipodystrophy population.
A later randomized trial published in JAMA in 2014 reinforced and extended that picture in 50 HIV-infected adults with abdominal fat accumulation. Tesamorelin 2 mg daily for six months produced a visceral-fat treatment effect of about −42 cm² compared with placebo, and additionally a modest reduction in liver fat. The reviewers of the broader program noted that the visceral-fat benefit was maintained out to about a year in people who stayed on treatment — but also that the fat re-accumulated after the drug was stopped, which tells you the effect depends on continued use.
On tolerability, the broader review of the development program found tesamorelin was generally well tolerated in these trials: serious treatment-emergent adverse events occurred in under 4% of patients over 26 weeks, and most side effects were either injection-site reactions or the kinds of effects expected from growth-hormone activity — joint pain, headache, and fluid-related swelling. That is a meaningful safety signal, but read it precisely: "generally well tolerated" is a statement about a specific, closely monitored patient group inside a clinical trial, not a promise that the same holds in healthy people self-administering the drug without that oversight.
Read together, these results justify the narrow approved claim and nothing wider. They were obtained in a specific patient group, at a specific dose, with defined monitoring, over months — not in healthy adults seeking body recomposition, and not as evidence about long-term safety, which the label explicitly says has not been established for cardiovascular outcomes.
| Trial | Dose & duration | Key result |
|---|---|---|
| Falutz 2007 (NEJM) | 2 mg/day, 26 weeks | Visceral fat −15.2% vs +5.0% on placebo; IGF-1 +81.0% |
| Stanley 2014 (JAMA) | 2 mg/day, 6 months | Visceral fat ≈ −42 cm² vs placebo; modest liver-fat reduction |
| Dhillon 2011 (review) | 2 mg/day, to 52 weeks | VAT reduction held to wk 52; reaccumulates after stopping; serious AEs <4% |
Why off-label / anti-aging use is different
Most of the popular interest in "tesamorelin dosing" is not about HIV lipodystrophy at all — it is about growth hormone optimization, fat loss, body composition, and anti-aging in otherwise healthy adults. None of those uses is FDA-approved. They are off-label, which is a meaningfully different category, not a footnote.
Off-label means there is no large body of randomized controlled trials establishing that tesamorelin is effective and safe for that purpose in that population, and no regulatory review of a dose for it. The theoretical appeal — that a GHRH analog nudges the body’s own GH pulses and preserves the natural feedback loop that limits GH excess — is biologically reasonable, but a plausible mechanism is not the same as validated benefit. The evidence standard simply is not there for healthy-population use.
There are also real reasons for caution. Even in the approved trials, the side effects tracked the GH pathway: joint pain (arthralgia), fluid retention and swelling (peripheral edema), injection-site reactions, and the potential for glucose intolerance — which is why the approved protocol builds in glucose monitoring and regular IGF-1 checks. Those risks do not disappear when the drug is used off-label; if anything, they are less well characterized in people who were never studied.
One contraindication in particular deserves a plain explanation, because it connects to why pushing GH and IGF-1 upward is not a free lunch. The approved label lists active malignancy as a contraindication. The biological logic is that IGF-1 is a growth-and-proliferation signal, and large observational studies have found that people with naturally higher IGF-1 levels carry a modestly higher risk of certain cancers, such as prostate and premenopausal breast cancer (PMID 15110491). That is an association, not proof that tesamorelin causes cancer — but it is exactly why deliberately raising IGF-1 is something a clinician weighs carefully, and why self-directed use sidesteps a judgment that should not be skipped.
What checks and monitoring does tesamorelin involve?
Even in its approved use, tesamorelin is not a fire-and-forget injection. The label and the trial protocols build in screening and ongoing monitoring, precisely because the drug is meant to raise growth hormone and IGF-1 — effects that have to be watched. Before starting, a prescriber checks for the contraindications the label lists: active malignancy, pregnancy, disruption of the hypothalamic-pituitary axis, and known hypersensitivity to the drug.
Once a person is on it, two kinds of lab matter most. IGF-1 is tracked to confirm the GH axis is responding without being driven too high — in the pivotal trial IGF-1 rose 81.0%, so it can climb fast, and an over-shoot is something a clinician wants to catch. Glucose handling is the other: because raising growth hormone can nudge blood sugar up and blunt insulin sensitivity, the approved protocol pairs the drug with glucose monitoring, typically fasting glucose and HbA1c, to catch any drift early.
The outcome that actually defines success is the visceral fat itself, usually followed with waist measurements or imaging rather than the bathroom scale (remember, the effect is weight-neutral). And because the benefit fades once the drug stops — the visceral fat re-accumulates — whether to continue, pause, or stop is a recurring decision a prescriber revisits, not a fixed course you finish and forget. All of this is one more reason the off-label, unmonitored version is a different and riskier proposition than the studied one: it strips out the very checks that made the approved use defensible.
Who decides
The honest answer to "what dose of tesamorelin should I take" is that it is not a question to answer from an article. Whether tesamorelin is appropriate at all — and if so, at what dose, with which formulation, and with what monitoring — is a clinical decision that belongs to a licensed clinician who can evaluate your full medical history.
A clinician weighs things a webpage cannot: your glucose tolerance and diabetes risk, joint and cardiovascular status, any history of malignancy or pituitary issues (which are contraindications on the approved label), what you are actually trying to achieve, and whether the intended use is the approved indication or off-label. They also order the baseline and follow-up labs — fasting glucose, HbA1c, IGF-1 — that make the drug safer to use and easier to stop if something drifts.
PeptidePanel does not sell, source, prescribe, or endorse tesamorelin or any compound, and nothing here is medical advice. The decision — for any indication, approved or off-label — belongs to you and your clinician.
Tracking a tesamorelin protocol on PeptidePanel
If a clinician has prescribed tesamorelin, the day-to-day record is where a protocol succeeds or quietly goes sideways — and that record is easy to lose track of in your head.
PeptidePanel is the neutral monitoring layer for exactly that work: logging each injection date, charting waist circumference and weight trends, and tracking the labs your clinician watches — fasting glucose and HbA1c to catch glucose dysregulation early, and IGF-1 against age-matched reference ranges — so both you and your clinician have a clear quantitative picture of how the protocol is performing. It does not supply, recommend, or prescribe anything. It is simply the organized notebook for the plan your clinician set.